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Summary 
A wide range of existing data sources could potentially be used to improve our 
understanding of arthritis in the Australian population. This working paper uses an 
assessment framework recently developed by the Australian Institute of Health and Welfare 
(AIHW) (AIHW 2014a) to assess the suitability of the Australian Rheumatology Association 
Database (ARAD) as a potential new data source for population health monitoring of 
inflammatory arthritis. 
More than 400,000 Australians have rheumatoid arthritis, the most common form of 
inflammatory arthritis (ABS 2012). This auto-immune disease causes chronic inflammation, 
pain and swelling of the joints and can greatly reduce a person’s quality of life. 
The ARAD, managed by the Australian Rheumatology Association, is a national registry that 
collects health information from individuals with inflammatory arthritis. It was primarily 
established to monitor the benefits and safety of new treatments, particularly the biological 
disease-modifying anti-rheumatic drugs (bDMARDs). 
The AIHW’s assessment of the ARAD for the purpose of national population health 
monitoring is that: 
• it has the potential to fill a range of identified data gaps in relation to key questions for 
monitoring arthritis, including treatment outcomes, disease progression, quality of life 
and economic impacts 
• it has well established administrative and governance arrangements in place to ensure 
data quality and compliance with legislative requirements 
• it has limited coverage which could potentially be improved by combining with, or 
linking to, other similar data sources 
• on balance, it is a data source with the potential to provide useful information for 
population health monitoring of inflammatory arthritis, particularly if used in 
combination with, or linked to, other data sources.  
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1 Introduction 
Within Australia, arthritis and other musculoskeletal conditions are highly prevalent, cause 
significant disability and generate substantial personal and health system costs. The Global 
Burden of Diseases Study 2010 ranked musculoskeletal disorders as the leading cause of 
disability in Australia and second only to cancer for overall disease burden (IHME 2010).  
Population health monitoring of arthritis and other musculoskeletal conditions is necessary 
to determine existing health patterns and population groups at risk; current health service 
usage; and future demands on the health system. It helps provide the evidence base to 
inform policies and programs to help prevent and better manage these conditions.  
It is a core role of the AIHW and its monitoring centres to explore the usefulness of a range 
of data sources for national monitoring purposes, to drive increased transparency and 
standardisation of national health datasets already in existence,  and to develop standards 
for new datasets.  
This working paper outlines the AIHW’s assessment of the suitability of the Australian 
Rheumatology Association Database (ARAD) for monitoring arthritis. This assessment 
draws heavily on the Data Quality Framework of the Australian Bureau of Statistics (ABS) 
(ABS 2009).  
1.1 What is inflammatory arthritis? 
More than 400,000 Australians have rheumatoid arthritis, the most common form of 
inflammatory arthritis (ABS 2012). This auto-immune disease causes the body’s immune 
system to mistakenly attack its own tissues, causing chronic inflammation, pain and swelling 
of the joints. It most commonly affects the hand joints and potentially leads to deformity and 
severe disability. Other forms of inflammatory arthritis include ankylosing spondylitis, 
juvenile idiopathic arthritis, and psoriatic arthritis.  
The impact of inflammatory arthritis is generally long-lasting and can greatly reduce quality 
of life. It can affect an individual’s physical, social and emotional functioning, and is 
associated with premature death. The peak onset for rheumatoid arthritis is in the fourth and 
fifth decades of life, thereby affecting individuals in their peak income-earning years 
(Buchbinder et al. 2007).  
Previously, the primary forms of disease-modifying treatment for inflammatory arthritis 
were the disease-modifying anti-rheumatic drugs (DMARDs). These drugs had a long 
history of use and a well-known risk profile. Since 2003, newer drugs have been introduced 
to the market—biological disease-modifying anti-rheumatic drugs (bDMARDs). These newer 
drugs have been found to greatly improve the health outcomes of patients with severe 
inflammatory arthritis. While the short-term efficacy of these newer drugs is well 
established, the long-term outcomes are not yet well known (Briggs et al. 2009, Buchbinder et 
al. 2007). 
bDMARDs have restricted access and can only be prescribed by rheumatologists and clinical 
immunologists. The availability of government-funded bDMARDs usage is restricted to 
patients who fail to achieve adequate responses to prior therapy and fulfil criteria for ‘severe 
and active disease’. Prior approval by Medicare Australia is required before bDMARD 
treatment on the Pharmaceutical Benefits Scheme (PBS) can be initiated.   
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Due to the uncertainty surrounding the long-term outcomes of bDMARDs, several countries 
have established long-term observational studies via the establishment of health registries to 
monitor the long-term safety and efficacy of these drugs (Briggs et al. 2009). The Australian 
Rheumatology Association Database (ARAD) was established with the primary aim of 
determining the effectiveness and long-term safety of biological drugs used to treat 
inflammatory arthritis conditions. 
1.2 What information is needed for monitoring 
inflammatory arthritis? 
Arthritis (including inflammatory arthritis) and other musculoskeletal conditions are chronic 
diseases for which information is required across the disease continuum to monitor the 
movement from wellness to mortality (see Figure 1.1). The different stages of disease 
progression include the well population; the at-risk/asymptomatic population; populations 
with a recent disease diagnosis; populations managing a chronic condition; populations 
receiving palliative care; and those who have died from the condition.  
Various data sources could potentially be used to provide information relevant to 
understanding arthritis and musculoskeletal conditions. Many of these data sources were not 
developed specifically for monitoring these conditions but have the potential to be used for 
population health monitoring.  
Information is needed to describe the situation at a particular point in time and also to track 
changes over time. These priority information areas translate into a set of 6 key questions for 
monitoring arthritis and other musculoskeletal conditions (see Box 1.1) (AIHW 2014b).  
 
Box 1.1: Key questions for monitoring arthritis and other musculoskeletal 
conditions 
1. Risk factors: What proportion of the population experiences modifiable risk factors 
associated with arthritis and other musculoskeletal conditions?  
2. Prevalence: What is the prevalence of arthritis and other musculoskeletal conditions in 
the population? 
3. Prevention, management and treatment: What prevention, management and treatment 
services do the population with arthritis and other musculoskeletal conditions receive? 
4. Quality of life: How do arthritis and other musculoskeletal conditions affect an 
individual’s quality of life? 
5. Disability and death: To what extent are disability and death associated with arthritis 
and other musculoskeletal conditions?  
6. Health expenditure: What is known about expenditure on arthritis and other 
musculoskeletal conditions? 
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 Stage of disease continuum 
 Well population 
 
At-risk or asymptomatic 
 
Diagnosis of disease 
 
Management of chronic 
disease  
Mortality 
Level of 
prevention 
Primary prevention 
 
Secondary prevention/early 
detection  
Disease management, tertiary prevention and rehabilitation 
 
Disease management 
Nature of 
intervention 
Promotion of healthy 
behaviours and 
environments across the life 
course: 
• Promote weight control(a) 
• Promote joint injury or 
trauma prevention(a)(c) 
• Prevent smoking(a)(b) 
• Promote behaviours to 
improve bone health 
including nutrition, 
exercise and moderate 
alcohol consumption(c) 
• Address occupational 
risks(d) 
Universal and targeted 
approaches 
 
Education programs 
Screening: 
• Bone mineral density 
screening(c) 
Identification of cases 
Periodic health examinations: 
• Promote weight control and 
joint injury prevention(a) 
• Early intervention, tailored to 
condition (for example, early 
recognition of symptoms and 
prompt referral to allied 
health/self-management(a)(d) or 
to specialist services as 
appropriate) 
• Intervene to prevent first 
fracture(c) 
Control risk factors  
Treatment and acute care, 
including pain management 
Complications management 
including comorbidity 
Preserve function and 
independence 
Promote healthy lifestyle 
behaviours: 
• Initiate disease-modifying 
therapy early(b) 
• Support attendance at an 
educational program(b)(c) 
• Consider occupational 
intervention(b) 
• Identify people with minimal 
trauma fracture(c) 
• Intervene to prevent further 
fractures(c)  
Continuing care 
Maintenance 
Optimise therapy and 
symptom relief: 
• Provide timely access to 
joint replacement surgery 
and multidisciplinary 
care(a)(b) 
Disability support and 
management 
Improve functioning (social 
and physical): 
• Self-management 
• Psychosocial support 
Intervene to prevent further 
fractures(c) 
Improve health-related 
quality of life  
Manage pain and 
discomfort 
Improve health-related 
quality of life 
Responsible 
sectors 
Public health initiatives 
Primary health care 
Other sectors  
Primary health care 
Public health initiatives 
 
Specialist services 
Hospital care 
Primary health care  
Primary health care 
Community care 
Specialist services  
Hospital care 
Primary health care 
Community care 
 Prevent movement to 
at-risk group  
Prevent/delay progression 
to complications  
Prevent progression to 
established disease  
Delay progression of 
complications  
 
(a) Particularly relevant to osteoarthritis. 
(b) Particularly relevant to rheumatoid arthritis. 
(c) Particularly relevant to osteoporosis. 
(d) Particularly relevant to back problems. 
Source: Modified from DoHA & NAMSCAG 2004; National Public Health Partnership 2001. 
Figure 1.1: Public health activities across the disease continuum for arthritis and other musculoskeletal conditions  
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1.3 What is the Australian Rheumatology 
Association Database? 
The ARAD, managed by the Australian Rheumatology Association, is a national database 
that collects selected health information from individuals with inflammatory arthritis and 
from their clinicians. The specific aims of the ARAD are to: 
• establish the short- and long-term effectiveness and safety of bDMARDS prescribed for 
rheumatoid arthritis and other inflammatory arthritis 
• identify the relative contributions of disease factors and other treatments in any risks or 
benefits observed 
• determine the economic impact of bDMARD therapy 
• inform rheumatologists of their individual patient outcomes, together with de-identified 
summary data as a comparison 
• evaluate the appropriateness of the stringent restrictions for the prescription of 
bDMARDS. 
The ARAD collects information from patients every 6–12 months via questionnaires, 
including questions about medical history, medication history, responses to medication, 
physical functioning and patient-reported quality of life. Patients also provide consent to link 
their registry information with other relevant data sources such as cancer and death 
registries, the PBS and Medicare Benefits Schedule data. Patients and rheumatologists across 
Australia contribute to the ARAD and have provided data for up to 10 years. 
1.4 Why assess the Australian Rheumatology 
Association Database? 
The ARAD has not featured in current monitoring reports produced by the AIHW. This is 
partly because it is not part of the national data sources routinely used for monitoring 
purposes for which nationally agreed data standards and data flow arrangements exist (for 
example hospital and deaths data). The ARAD had also not been previously assessed to 
determine its strengths and limitations for population health monitoring, including its 
content, completeness and governance arrangements.  
This working paper uses the AIHW’s recently developed assessment framework (AIHW 
2014a) to assess the suitability of the ARAD as a potential new data source for population 
health monitoring of inflammatory arthritis. The ARAD was selected for this demonstration 
project because: 
• it focuses on inflammatory arthritis, a group of musculoskeletal conditions for which 
there is particularly limited information  
• it holds detailed information about patient treatment and patient reported outcomes 
(quality of life) over time, both identified information gaps and priorities 
• of its potential to support data linkage and thereby analysis of patient movements 
across health settings and patient outcomes (given its methodology includes consent 
arrangements to undertake linkage to other specified datasets).  
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2 Assessment of the ARAD 
When identifying potential data sources for population health monitoring, it is important to 
ensure they are ‘fit-for-purpose’. The AIHW’s 3-step process to assess potential data sources 
for population health monitoring includes: 
• Step 1—collecting information about the data source 
• Step 2—identifying the potential to inform key monitoring areas 
• Step 3—assessing the quality of the data, using a modified version of the Australian 
Bureau of Statistics (ABS) Data Quality Framework (ABS 2009), to determine its  
‘fitness-for-purpose’ by establishing strengths and limitations.  
Further details of the assessment process are outlined in the recent report An AIHW 
framework for assessing data sources for population health monitoring (AIHW 2014a). Steps 1 and 2 
of the assessment framework for the ARAD were previously completed as part of the 
recently published report documenting potential data sources for monitoring 
musculoskeletal conditions (AIHW 2014b) and are included in tables 2.1 and 2.2 below.   
Step 1—Collect data source information 
Table 2.1: ARAD data source details (Step 1) 
Name Australian Rheumatology Association Database (ARAD) 
Type of data source Registry (national) 
Brief description The ARAD is primarily a national database for patients with inflammatory arthritis 
commencing treatment with bDMARDs following consultation with a rheumatologist. Also 
included in the database are patients with rheumatoid arthritis, juvenile idiopathic arthritis, 
ankylosing spondylitis and psoriatic arthritis who commenced treatment with bDMARDs as 
well as a ‘control’ group not on bDMARDs. 
The database contains information on participants’ location, arthritis history, health status 
(including quality of life and other health conditions), and treatment history (including adverse 
reactions to medication). For some participants the database also contains information about 
arthritis status (including tender and swollen joint count) and markers of inflammation. 
Purpose To determine the effectiveness and safety of new biological drugs (bDMARDs) used to treat 
inflammatory arthritis. 
Collection methodology Information is collected from patients every 6 to 12 months via questionnaires. Ongoing 
permission is sought to collect information from state and national registries and all other 
relevant health records for the life of the registry. 
Scope (theoretical coverage 
of relevant population) 
Patients of participating rheumatologists. The study focuses on patients with inflammatory 
arthritis commencing treatment with bDMARDs, but also includes, as a control group, patients 
with inflammatory arthritis not taking this class of drugs.  
Coverage (actual) At December 2013, 3,170 participants completed questionnaires and a further 2,112 agreed 
to allow information to be gathered from state and national registries. Out of 342 registered 
rheumatologists in Australia, there are 268 participating in ARAD. 
Geographic coverage Australia. 
Frequency/timing Commenced in 2002 and is ongoing. 
Basic collection count Person. 
Size As at July 2013, there were over 5,000 participants and over 30,000 completed 
questionnaires. 
Collection management 
organisation 
Australian Rheumatology Association, with support from Monash University, Cabrini Health, 
Royal North Shore Hospital, University of Sydney, St George Hospital, University of New 
South Wales and the Centre for Clinical Research Excellence at Monash.  
Further information <http://www.arad.org.au/Public/Home.aspx>. 
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Step 2—Identify potential for data source to inform 
priority information areas 
Table 2.2: Priority information areas for population health monitoring (Step 2) 
Priority Information Area Details 
Risk factors Information on all common comorbid conditions and potential triggers and risk factors such as 
smoking, alcohol, education, social status, occupational history. 
Prevalence and 
incidence 
No data regarding the diseases but collection of incidence data on adverse events, 
hospitalisations and new diseases such as cancer, serious infections, TB and so forth. 
Prevention, treatment 
and management 
Full information on treatment history, including medication use, complementary and over-the-
counter treatments, hospitalisation and adverse drug reactions. 
Quality of life Comprehensive data on self-assessed quality of life using several standard instruments including 
a utility instrument. 
Disability and death Comprehensive data on disability burden via self-assessed disability tools. Death available by 
data linkage and carer reports. 
Expenditure, costs Full data on over-the-counter and complementary medicine use. It’s also possible to link to the 
PBS in terms of drug utilisation, and to the MBS in terms of health services utilisation. 
Socio demographics Patient location, education, social factors, occupation history, pension status. Personal identifiers, 
such as name, date of birth, contact details, Medicare number and an alternative contact. 
Step 3—Assess individual data quality elements 
Step 3 of the AIHW’s framework consists of assessing 7 data quality elements (see Figure 2.1).  
 
 
Source: Adapted from the ABS’s Data Quality Framework (ABS 2009). 
Figure 2.1: Seven elements for assessing data quality (Step 3) 
 
Institutional 
environment 
Relevance 
Timeliness 
Accessibility Interpretability 
Accuracy 
Coherence 
Seven elements 
of data quality 
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The 7 elements of data quality include the institutional environment; timeliness; accessibility; 
interpretability; relevance; accuracy; and coherence. Each individual data quality element 
will be assessed in the subsequent text and then an overall assessment of Step 3 presented at 
the end of the chapter, along with a summary table (see Table 2.4). 
Institutional environment 
Key questions in the assessment of the data collection’s institutional environment are: 
• Is the production and dissemination of data undertaken in an objective, professional and 
transparent manner? 
• Is the agency producing the data independent and free from potential conflicts of 
interest? 
• Are there sufficient resources for the collection and production of the data? 
• Are there processes, staff and facilities in place to ensure data quality? 
• Does the data source comply with privacy and legislative requirements for managing 
data?  
Governance arrangements  
The ARAD governance arrangements are shown in Figure 2.2. The Australian Rheumatology 
Association owns the ARAD and controls access to, and release of, the data contained within 
it. The management of the database is the responsibility of the ARAD management 
committee which reports directly to the executive. The ARAD scientific advisory committee 
also reports to the executive and is responsible for advising on policy and access to the data. 
Research proposals, which have ethics approval, are submitted to the scientific advisory 
committee.  
The day-to-day management of the database is the responsibility of the project coordinator, 
3  state research officers and a data management centre team comprising a database 
architect, data manager and research assistant. These appointees work in close association 
with the management committee. The Australian Rheumatology Association and Monash 
University administer the funds and an audited account is presented to the executive 
monthly and to the full membership annually. 
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Figure 2.2: Australian Rheumatology Association Database governance arrangements 
A preliminary assessment, undertaken by the AIHW of the ARAD against the Operating 
Principles for Clinical Quality Registries (ACSQHC 2010)—relevant here given the nature of 
this dataset—demonstrated a strong commitment by the ARAD management team to ensure 
the quality, comprehensiveness and usability of data collected. Many of these operating 
principles are consistent with the elements of the AIHW’s data quality assessment 
framework. 
Funding 
The database was initially funded from unconditional educational grants to the Australian 
Rheumatology Association from pharmaceutical companies involved with new therapies for 
arthritis, including the bDMARDs. In 2006, maintenance and further development of the 
ARAD was funded by a National Health and Medical Research Council Enabling Grant 
(Number 384330) and by Monash University. The ARAD is currently funded via 
unconditional educational grants from pharmaceutical companies. Sustainability of funding 
has been identified as a key issue by the ARAD management team. 
Ethics approval 
Ethics approval for the ARAD has been obtained from 23 committees and organisations 
across Australia (see Appendix 1). The primary ethics committee for the ARAD is that of the 
Cabrini Hospital. As part of the ethics approval process, ARAD personnel need to be familiar 
with, and abide by, the requirements set out in relevant privacy legislation, the National 
Statement on Ethical Conduct in Human Research and the Australian Code for the 
Responsible Conduct of Research. 
Recruitment and data collection  
The recruitment and data collection process is shown in Figure 2.3. Patients visiting a 
rheumatologist and subsequently prescribed bDMARDs are invited to participate in the 
ARAD by the rheumatologist. 
Ownership 
Australian Rheumatology Association (ARA) 
Database management 
ARAD management committee 
ARA executive 
Policy advice and data access 
ARAD scientific advisory committee 
Day-to-day management 
Project coordinator 
State research officers 
Data management centre 
Reporting 
ARA membership 
Reporting 
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The patient provides their contact details and signs to receive information on the ARAD. 
These documents are sent to the ARAD Data Management Centre. The relevant state 
research officer then contacts the patient and provides further information and the 
standardised baseline questionnaire for self-completion. Patient consent is also obtained to 
access their Medicare and national/state health registry data for data linkage (National 
Death Index; Australian Cancer Database; state and territory cancer registries).  
Follow-up questionnaires are mailed every 6 months. Patients with inflammatory arthritis 
not taking a bDMARD are also asked to participate as study controls. (Note that those in the 
control group may have less severe inflammatory arthritis at the time of recruitment and so 
caution needs to be exercised when making comparisons.) 
 
Source: Buchbinder et al. 2007. 
Figure 2.3: ARAD recruitment and data collection processes 
  
Patient presents to rheumatologist 
bDMARD prescribed 
Rheumatologist and patient complete 
‘permission to contact form’ 
Form faxed to ARAD data 
management centre  
Patient contacted by ARAD team 
member 
Consent and entry questionnaire sent 
to patient via email or post 
Questionnaire returned to data 
management centre for scanning or 
online questionnaire completed 
6-month questionnaire sent to patient 
Annual report sent to 
rheumatologist 
Data queries handled by 
research officers 
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Data collection and entry 
The ARAD data are protected through secure access and transfer controls, in line with 
relevant legislation, regulation, standards and guidelines. Skilled data entry personnel check 
the data and correct errors. The ARAD data are stored in a password protected-database and 
data are transferred via a secure file transfer system. Participants receive an individual link 
to their online questionnaire and log in with their date of birth and postcode. 
Relevance 
Key questions in the assessment of the data collection’s relevance are: 
• Does the data collection measure the concept identified by the end user of the data? 
• Is the data source representative of the target population identified by the end user of the 
data?  
Data collected through the ARAD 
The ARAD questionnaire has been designed to ensure collection of all the data elements 
needed to assess the safety and effectiveness of biological drugs used to treat inflammatory 
arthritis. Of potential relevance for population health monitoring, the ARAD collects detailed 
information over time about patient treatment and patient-reported outcomes (quality of life) 
from individuals with inflammatory arthritis. This has been acknowledged as an identified 
data gap for monitoring purposes (AIHW 2014b).  
Data collected also includes lifestyle risk factors (for example, smoking, alcohol consumption 
and weight) and comorbidities (for example, heart disease and diabetes) which allows for 
these factors to be controlled for in any analysis. The data currently collected as part of the 
ARAD from the rheumatologist, patient and through record linkage are presented in 
Table 2.3.  
Table 2.3: Data collected at as part of the Australian Rheumatology Association Database 
Rheumatologist data Patient data Record linkage data 
Rheumatologist ID code Patient identifying information (Medicare 
number, date of birth) 
Australian Cancer Database 
Diagnosis Demography (age, gender, race, marital 
status, education) 
Medicare Australia  
bDMARD prescribed History of arthritis National Death Index 
Baseline erythrocyte sedimentation rate Medical history (illness, infection, cancer, 
symptoms) 
State and territory cancer registries 
Baseline C-reactive protein Smoking and alcohol consumption history  
Baseline joint count Medication history  
Chest x-ray result Reasons for ceasing medication for arthritis   
Mantoux test result Adverse events  
 Global evaluation of disease activity  
 Health Assessment Questionnaire  
 Assessment of quality of life  
 Short Form–36 Health Survey  
 European Quality of Life Survey  
 Assessment of the ARAD for national population health monitoring 11 
For the initial data entry, the rheumatologist provides clinical data, while the patient 
provides identifying information, demographic details and information on their medical 
history. Patients provide information on risk factors; disease type and years of arthritis 
symptoms; medication history; and health-related quality-of-life measures.  
Quality-of-life instruments include: the 36-Item Short Form Health Survey (SF-36), the 
Assessment of Quality of Life (AQoL), the EQ-5D, and arthritis-specific disability assessed by 
the ‘physical function’ scale of the Health Assessment Questionnaire (HAQ). This data 
source has an extensive amount of personal information linked to medication use and health 
outcomes. 
Representativeness of the target population 
As shown in Figure 2.3, the recruitment and data-collection process relies on a number of 
important steps. Coverage is therefore dependent on: 
• sufferers of inflammatory arthritis visiting a rheumatologist 
• these patients being prescribed bDMARDs (only once the above condition is met) 
• the rheumatologist informing the patient about ARAD, completing a ‘permission to 
contact’ form and providing clinical data 
• the patient completing the baseline questionnaire 
• the patient completing 6-monthly questionnaires. 
This is visually represented in Figure 2.4. 
 
 
Note: There is a pathway for self-referral; however, the uptake is small through this process. 
Figure 2.4: Coverage of the Australian Rheumatology Association Database 
  
Australians with 
inflammatory arthritis 
Australians with 
inflammatory arthritis 
who see a 
rheumatologist 
Australians with 
inflammatory arthritis 
who see a 
rheumatologist and 
are prescribed 
bDMARDs 
ARAD 
Australians with 
inflammatory arthritis 
who see a 
rheumatologist, are 
prescribed bDMARDs 
and are enrolled 
 12 Assessment of the ARAD for national population health monitoring  
It is difficult to completely verify the generalisability of ARAD data to all Australians 
receiving biological drug therapy for inflammatory arthritis. However, ARAD participants 
are drawn from all over Australia and from a variety of settings including hospital and 
community-based care, and from metropolitan, regional, and rural practices. Participants 
appear to be nationally representative (Williams et al. 2011). It has been verified that the 
majority of eligible patients of participating rheumatologists are asked to participate in the 
ARAD (Briggs et al. 2009).  
Participant numbers 
Participants are thought to represent about a quarter of all patients with inflammatory 
arthritis who have been exposed to biologic therapy in Australia. As such, a degree of 
selection bias may exist, with further investigation needed to determine the comparability of 
those in the ARAD with those not in the ARAD. As at February 2014, 3,102 participants are 
completing questionnaires and a further 2,137 have agreed to allow information to be 
gathered from state and national registries (1,558 of whom have completed at least 1 
questionnaire). There are 35,000 completed questionnaires in total. Just 276 patients signed 
up in 2013, down from 440 in 2012 and 1,434 in 2007. About 15% of participants have not 
been exposed to bDMARDs and serve as a control group.  
The number of participants completing questionnaires every 6 months decreases over time 
and so retention is difficult. As at January 2014, there is a 79.6% response rate for online and 
73% response rate for paper follow–up questionnaires. Out of 342 registered rheumatologists 
in Australia, 268 are participating in the ARAD (approximately 75%). However, just 55 
rheumatologists provided patients to the ARAD in 2013 (ARAD 2013). 
Timeliness 
Key questions in the assessment of the data collection’s timeliness are: 
• Are the data up-to-date and current? 
• Are there likely to be subsequent surveys or data collections? 
Participants completing paper-based surveys are entered into the database within 1 week 
and there is no delay in the availability of data submitted by online participants. Once the 
data have been entered into the system, many items are automatically flagged for validation, 
such as cancer reports, serious infections, incomplete bDMARD medication dates and 
hospitalisations. These data queries may take up to 1 month depending on the ease of contact 
with the patient and/or health provider. It is anticipated that, subject to funding, data 
collection will be ongoing. 
Accessibility 
Key questions in the assessment of the data collection’s accessibility are: 
• Are there processes in place to facilitate data access? 
• Can the data source be provided in a timeframe suited to the user’s requirements? 
• Are the data available in suitable formats? 
• Are data available at costs affordable to the user’s project? 
Procedures are in place for external researchers to access the ARAD database. Researchers 
need to submit an expression of interest form, a research proposal and ethics approval from 
the researcher’s institution to the ARAD Scientific Advisory Committee for consideration. If 
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access to patient personal information is required then an ‘ARAD Confidentiality Agreement 
for External Researchers’ must be completed and signed by all project staff before the 
information can be released. 
Research proposals need to be approved by the ARAD Steering Committee before data 
requirements are sent to the data management centre. The average time for this process is 
about 6 weeks. 
ARAD data formats 
Data are generally provided in STATA format. However, if requested, data may also be 
available in other formats including Excel and SPSS. When the data file contains identifiable 
information, the file is transferred via a secure website (to which users are granted access 
with a username and password), in accordance with the Health Records Act 2010 and Privacy 
Act 1988.   
Interpretability 
Key question in the assessment of the data collection’s interpretability are: 
• Are metadata available to support appropriate interpretation of the data? 
A data dictionary/definitions manual is provided along with the dataset. This identifies the 
variables used in the data file and the corresponding item on the survey. The codes for each 
variable are also specified. 
Accuracy 
Key questions in the assessment of the data collection’s accuracy are: 
• Do the data reflect the condition or situation they were designed to measure? 
• Are potential or acknowledged sources of error described? 
To ensure the success of the registry, the process of quality control and data validation 
undergoes continued development and refinement. Researchers take a random sample of 
rheumatologist records to assess the concordance of patient responses concerning history of 
malignancy and adverse events to arthritis medications  They also determine concordance 
through record linkage with the State cancer registries through the Australian Cancer 
Database. 
In addition, the ARAD data query system identifies missing data when the questionnaire 
arrives at the data management centre. Other processes to ensure database quality include: 
• minimising selection bias by developing a tracking log for participating rheumatologists 
to ensure all patients starting bDMARDs are invited to participate in ARAD 
• regularly updating the standard operating procedure manual to reduce the number of 
data queries 
• regularly updating database programs to identify any contradictory information 
provided by patients 
• developing a spontaneous reporting scheme for rheumatologists to report adverse 
events. Information about adverse events is also to be forwarded to the Adverse Drug 
Reactions Advisory Committee. 
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Coherence 
Key questions in the assessment of the data collection’s coherence are: 
• Does the data source use standard concepts, classifications and target populations? 
• Does the data source use methodologies comparable with other data collections? 
The ARAD uses standard data collection measures and standardised quality-of-life 
questionnaires, where applicable, to enable meaningful comparisons to be made and to 
enable linkage to other Australian and overseas arthritis registries and databases. The ARAD 
is supported by a data definitions manual which provides a reference for the ARAD field 
definitions and codes. This publically available manual ensures a consistent approach to data 
collection and entry. 
Observational and longitudinal observational studies can provide information about the 
course and outcome of long term conditions that are difficult to obtain from other types of 
studies, such as randomised controlled trials. To help ensure the comparability between 
different longitudinal studies, it is useful to include agreed core variables. The data collected 
through the ARAD meet the Outcome Measures in the Rheumatology IV preliminary core 
set of domains for longitudinal observational studies in rheumatology. 
Linkage to other registries and databases enables validation and verification of data reported 
by participants.  
Summary assessment  
A summary of the AIHW’s assessment of the 7 data-quality elements of the ARAD are 
presented in Table 2.4. This assessment shows a strong commitment by the ARAD 
management team to ensure the quality, comprehensiveness and usability of data collected 
for ARAD. The production and dissemination of the ARAD data are undertaken in an 
objective, professional and transparent manner. There are also administrative and 
governance processes in place to ensure data quality and compliance with legislative 
requirements.  
While the concept measured by the ARAD is highly relevant for the purpose of monitoring 
arthritis, the registry only includes about 25% of all patients with inflammatory arthritis 
taking bDMARDs with the participation of about 75% of rheumatologists in Australia. 
Consequently, the data source is considered to be only partially representative for national 
monitoring purposes. 
The ARAD would provide timely data, in suitable formats with sufficient supporting 
information (metadata), to allow correct interpretations to be made. The ARAD data source 
would also provide relevant information on treatment, quality of life and disease 
progression. 
The ARAD has been designed to collect the necessary data elements for assessing the safety 
and effectiveness of biological drugs used to treat inflammatory arthritis. To ensure the 
accuracy and quality of the data, the ARAD uses standard data collection measures to enable 
meaningful comparisons to be made and to enable linkage to other registries and databases. 
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Table 2.4: Assessment of the ARAD’s ‘fitness for purpose’ for national monitoring of 
musculoskeletal conditions (Step 3) 
Data quality 
element Key question Yes Partially No 
Institutional 
environment 
 
Is the production and dissemination of data undertaken in an 
objective, professional and transparent manner? x   
Is the agency producing the data independent and free from 
potential conflicts of interest?  x  
Are there sufficient resources for the collection and production of 
the data?  x  
Are there processes, staff and facilities in place to ensure data 
quality? x   
Does the data source comply with privacy and legislative 
requirements for managing data? x   
Relevance 
 
Does the data collection measure the concept identified by the end 
user of the data? x   
Is the data source representative of the target population identified 
by the end user of the data?  x  
Timeliness 
 
Are the data up-to-date and current?  x   
Are there likely to be subsequent surveys or data collections? x   
Accessibility 
Are there processes in place to facilitate data access (e.g. ethics 
committees where appropriate; data transmission arrangements) x   
Can the data source be provided in a timeframe suited to the 
user’s requirements? x   
Are the data available in suitable formats? x   
Are data available at costs affordable to the user’s project? x   
Interpretability Are metadata available to support correct interpretation of the data? x   
Accuracy 
Do the data reflect the condition or situation they were designed to 
measure? x   
Are potential or acknowledged sources of error described? x   
Coherence 
Does the data source use standard concepts, classifications and 
target populations? x   
Does the data source use methodologies comparable with other 
data collections? x   
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3 Findings 
This working paper uses the AIHW’s newly developed assessment framework for 
population health data sources (AIHW 2014a) to assess the suitability of the ARAD as a 
potential data source for population health monitoring of inflammatory arthritis.  
Assessment findings for steps 1 and 2 
The ARAD is a voluntary national registry that collects longitudinal health information, 
including quality-of-life measures, from individuals with inflammatory arthritis. The 
database, managed by the Australian Rheumatology Association, monitors the benefits and 
safety of new treatments, particularly the bDMARD drugs. (Database details are included in 
Table 2.1). 
There is a known information gap relating to information on the treatment and management 
of arthritis and the resultant impact on quality of life (AIHW 2014b). The ARAD has the 
potential to fill a range of data gaps in relation to key questions for monitoring arthritis and 
other musculoskeletal conditions, namely those relating to treatment outcomes, disease 
progression, quality of life and economic impacts. (Database details are included in 
Table 2.2). 
Assessment findings for step 3 
The AIHW’s assessment of the ARAD ‘fitness-for-purpose’ for population health monitoring 
is summarised in Table 2.4. The assessment shows that the ARAD has well-established 
administrative and governance arrangements in place to ensure data quality and compliance 
with privacy and legislative requirements. The concepts measured and collected in the 
ARAD are considered relevant for the key monitoring areas for arthritis, such as treatment 
outcomes and quality of life for individuals with inflammatory arthritis.  
The AIHW has determined that the ARAD is likely to provide timely data, in suitable 
formats with sufficient supporting information (metadata) to allow correct interpretations to 
be made. The ARAD also uses standard data-collection measures and so meaningful 
comparisons and linkages can be made to other registries and databases. 
One potential limitation of the database is its coverage. Participants are thought to represent 
about a quarter of all patients with inflammatory arthritis who have been exposed to biologic 
therapy in Australia. Difficulties in retaining participants have been noted and recently 
numbers participating in the ARAD have declined slightly.  
Possible future uses of the ARAD 
Potential future uses of the ARAD for population health monitoring of arthritis could 
include investigating the following: 
• recipients of joint replacement surgery, through data linkage using patients on DMARDs 
as controls 
• patterns of death among people using bDMARDs, by linking ARAD to the National 
Death Index 
• long-term adverse effects of bDMARDs, by linking ARAD with cancer registries 
• disease progression of patients treated with bDMARD medication, by linking ARAD to 
the MBS/PBS, using patients on DMARDs as controls. 
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‘On balance’ assessment 
Potential to inform policy 
When assessing the usefulness of the ARAD, it is important to first establish its suitability 
and relevance to help inform policy questions and to fill information gaps. There is a known 
information gap relating to information on the treatment and management of arthritis and 
the resultant impact on quality of life (AIHW 2014b).  
Improving treatment and care for people with inflammatory arthritis can help prevent or 
slow disease progression, reduce pain, preserve independence and improve quality of life. 
Early diagnosis of rheumatoid arthritis, the most common form of inflammatory arthritis, 
can alter the course of the disease, prevent or delay joint damage and improve long-term 
outcomes. If poorly treated, inflammatory arthritis can be highly disabling and can cause 
progressive and irreversible joint damage and loss of function. 
More than half (58%) of all people with rheumatoid arthritis are of working age (25 to 64 
years). Within 5 years of diagnosis, up to 20% of people can no longer work due to their 
condition (Arthritis Australia 2014).  
The AIHW notes that the ARAD contains relevant data on self-assessed quality of life using 
several standard instruments, including a utility instrument. In addition, the ARAD also 
contains data on treatment outcomes, disease progression and employment status for people 
with inflammatory arthritis.  
Data source assessment of ‘fitness for purpose’ 
Once it is established that a data source has the potential to provide policy-relevant 
information, the next step is to undertake further assessment to determine if the data source 
is ‘fit-for purpose’(that is, suitable for population health monitoring). As noted in Chapter 2, 
the AIHW’s assessment of the ARAD shows the production and dissemination of the ARAD 
data are undertaken in an objective, professional and transparent manner and that 
governance processes are in place to ensure data quality and compliance.  
There are particular data quality elements where the dataset presents some challenges in 
terms of its suitability of population health monitoring. This includes the potential 
perception of its independence (based on the funding involvement of pharmaceutical 
companies); the lack of secure ongoing funding; and the incomplete coverage of the desired 
target population (which may affect the representativeness of findings).  
Benefits of data linkage 
The coverage of the ARAD could be improved by linking to other similar data sources such 
as the Optimising Patient Outcomes in Australian RheumatoLogy (OPAL) database. When 
considering potential uses for data linkage, it is important to specify the purpose of the data 
linkage and identify what policies it may contribute to. 
Data linkage of the ARAD to other data sources, such as the MBS/PBS and cancer registry 
data, could also provide valuable information on patient movements across health settings, 
disease progression and treatment outcomes. Rheumatoid arthritis is also associated with 
increased mortality (Arthritis Australia 2014) and this could be further investigated by 
linking the ARAD with the National Death Index. 
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Overall assessment 
Despite its incomplete coverage, the AIHW considers the ARAD has the potential to help fill 
identified data gaps relevant for national population health monitoring of musculoskeletal 
conditions. 
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Appendix 1 
The ARAD Human Research Ethics Committee (HREC) approvals (as of 
January 2014) 
Institutes/Hospitals 
1. ACT Health HREC  
2. Australian Institute of Health & Welfare Ethics Committee  
3. Cabrini Hospital HREC  
4. The Cancer Council New South Wales  and New South Wales Health HREC  
5. Western Australian Health HREC  
6. Department of Veterans' Affairs HREC  
7. Monash University Research Ethics Committee 
8. Northern Sydney Local Health District Human Research Ethics Committee  
9. Princess Margaret Hospital (WA) HREC  
10. Royal Children's Hospital Victoria HREC  
11. South Australia Department of Health HREC  
12. South Eastern Sydney Local Health District HREC  
13. St Vincent's Hospital (Melbourne) HREC  
14. The Tasmania Health and Medical HREC 
15. The Women’s & Children’s Health Network HREC  
16. Sydney Children’s Hospitals Network HREC 
Cancer registries 
17. Australian Capital Territory Cancer Registry 
18. Queensland Cancer/Department of Health  
19. Northern Territory Department of Health 
20. Victoria Cancer Council 
21. Tasmania Cancer Registry 
22. South Australia Cancer Registry 
23. Western Australia Cancer Registry 
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